Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 16% below Graham Number — thin margin of safety
- Piotroski F-Score 6/9 — moderate financial health
- Strong ROE of 32.0% with 19.2% net margin
SOLVENTUM CORPORATION (SOLV) is a Healthcare company operating in Surgical & Medical Instruments & Apparatus, listed on the NYSE , with a market capitalisation of $11.4 billion . Key value metrics: P/E ratio 7.1, P/B ratio 2.26, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 3 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
SOLVENTUM CORPORATION — Fundamental Analysis Summary
SOLVENTUM CORPORATION (SOLV) is trading 16% below its Graham Number of $78.07, offering a thin margin of safety. The stock carries a low trailing P/E ratio of 7.1x.
On financial health, SOLV shows a moderate Piotroski F-Score of 6/9, and strong return on equity of 32.0% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 1.00.
StockPik's composite Value Score for SOLV is 100/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
SOLV reports a solid gross margin of 54.6% (sector average: 33.5%) and a strong operating margin of 27.7%.
SOLV shows revenue growing at 1% year-over-year, with earnings growing at 225%.